Candel Pairs HSV Vectors with Carl June's CAR-T Cells in Solid Tumor Pact

Candel Therapeutics revealed a collaboration with the University of Pennsylvania Wednesday to assess the combination of Candel’s herpes simplex virus (HSV) vectors and UPenn’s CAR-T cell treatments in solid tumor models.